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Abstract 
Stricter bioequivalence criteria are in place for generics where there are narrow therapeutic indexes such as generic 
immunosuppressives, enhancing their acceptance despite limited published studies. No serious issues have been 
reported to date with generic ciclosporine despite being on the market in Europe for more than 10 years 
 
Manuscript 
 
Regulatory bioequivalence rules for usual generics are well-established and already recognized. However, for narrow 
therapeutic index drugs and immunosuppressives, there are specific and tighter criteria in place. 
 
Drugs with a narrow therapeutic index are defined by a narrow distance between the dosage that induces a desired 
effect and that dosage which already has a toxic effect. Typically, this ratio in the field of pharmacology is indicated 
by the quotient of LD50/ED50 (LD50 = the dose at which 50% of the animals die, ED 50 = the dose at which 50% of 
the animals show the desired effect). Alternatively, the quotient of LD5/ED95 can be used, which can better illustrate 
a non-linear dose-response curve.  
 
For a perfectly safe drug, the ratio should therefore be very high. If in contrast the ratio is low, i.e. if a drug shows a 
value of only 3 or 4, this is called a "Narrow Therapeutic Index-Drug" (NTI), which must always be dosed with 
particularly high accuracy. Even a minor variation in plasma levels may lead sometimes to treatment failure on the 
one hand or inevitably to toxic effects on the other. Examples of such agents typically include immunosuppressants, 
digitalis, theophylline, and some anti-epileptic drugs.  
 
The acceptance range of bioequivalence trials which is usually applied for a marketing authorization of a generic drug 
is 80.00-125.00% of the 90% confidence interval of WKHUDWLRRIWKHWHVWDQGUHIHUHQFHSURGXFWV¶$8&(Area Under 
the Curve) and Cmax (maximum plasma concentration). For drugs with a narrow therapeutic index, and especially 
for immunosuppressives, the European Medicines Agency (EMA) demands even greater accuracy in justified cases 
and therefore has set more stringent criteria although in practice ratios for authorized conventional generics usually 
differ on average by only 3 to 4 percent from their originator [1-4].  
 
(0$¶Voverhauled bioequivalence (BE)-guideline [5], in force since 2010, requires that for potential narrow 
therapeutic index drugs  the (0$¶s Pharmacokinetic-Working Party (PKWP) [6] will evaluate if a generic drug newly 
submitted for authorization is to be thought of as an NTI and whether for this NTI actually stricter bioequivalence 
criteria have to be applied. It is important for a pharmaceutical manufacturer or applicant to know that there is no 
pre-casted list that names all such agents, but that all agents submitted for generic authorization will be evaluated by 
the authority on a case by case basis with regard to their NTI-requirements. 
 
Examples where this has already been practiced i are the regulatory requirements for ciclosporin and tacrolimus 
generics as described in a PKWP Questions and Answers- (Q & A) document published on the EMA website [7]. In 
the case of these two immunosupressives, restricted bioequivalence criteria were set. 
 
For ciclosporin, narrower acceptance intervals of 90.00-111.11% are required for both the AUC and the Cmax. 
Whereas, for tacrolimus the narrow acceptance interval is only required for the AUC but is not required for the Cmax. 
  
This is because tacrolimus plasma levels show accumulation with repeated dosing, resulting in a lower relevance 
being given to differences in initial peak plasma concentrations. 
 
The narrower acceptance range limits for the confidence intervals for NTIs (Fig.1) provide a greater confidence in the 
true bioequivalence for these drug substances. However, this requirement significantly increases the number of 
subjects necessary for the bioequivalence (BE)  studies. Tacrolimus, for example, is a drug which is not merely an 
NTI, but additionally shows relatively high intra-individual variation in plasma levels. It has a relatively high 
coefficient of variation (CV), close to 30%, which would classify it as a highly variable drug. Even in bioequivalence 
trials of tacrolimus, when a conventional acceptance range is applied, this would typically necessitate enrolling a 
substantially higher numbers of trial participants than in the usual, BE-Guideline requiring a minimum of 12 to 24 
subjects. One would need at least 40 subjects for a tacrolimus product, and in fact to demonstrate compliance with 
the (0$¶Vmandatorily required, narrower acceptance limits, might require up to 200 to 300 subjects. 
 
To increase the safety of generic immunosuppressives even more,  it is also recommended that the summary of 
product characteristics (SPC) states that patients who are prescribed either a generic immunosuppressant after an 
originator or are switched in any other way, have their plasma levels monitored during the time of the switch to 
avoid potential rejection [8]. This is however similar to what is undertaken in normal clinical practice when patients 
are first placed on an immunosuppressant after receiving  a solid organ graft.  
 
Because of the issues concerning generic immunosuppressive medicines, Molnar et al recently undertook a 
systematic review and meta-analysis of all available studies since 1980 comparing generic with originator (innovator) 
immunosuppressive medicines [9]. The authors documented that acute rejection was rare in transplant patients 
given generic immunosuppressive medicines and the incidence of rejection did not differ between the groups. 
However, as recently stated, the methodological standard of the published studies included was very variable and 
follow-up times were short [10].  
 
In the evaluation of the pooled pharmacokinetic data Molnar et al  showed that the generics met the FDA 
bioequivalence criteria, but did not all meet the stricter EMA criteria [9].  It appears that the small number of patients 
in some of the included studies, and as a result  the wide confidence intervals, significantly contributed to this 
finding. For statistical reasons, in order for results to meet the stricter acceptance criteria for immunosuppressives, 
requiring narrow confidence intervals, a sufficiently higher number of patients must be included in the trials [11].  
 
This effect on subject numbers needed is illustrated by the wide confidence intervals found in immunosuppressive 
studies with less than 20 subjects. As reviewed in the paper by Molnar et al, only trials with approximately 50 to 70 
patients were able to fulfill the EMA acceptance criteria [9]. In detail, their sub analysis of two randomized kidney 
trials showed that with a mean of 30 subjects, both failed to fulfill the stricter EMA bioequivalence criteria whereas 
the pooled sub analysis of seven non-randomized interventional kidney studies with a 53% higher mean sample-size 
of 46 patients did fulfill these criteria.  
 
1RWDEO\WKHPHDQUDWLRVRIWKHWHVWDQGUHIHUHQFHSURGXFWV¶$8&DQG&PDx in most of the reported trials were well 
within the expected range [12]; and were in fact only a few percentage points higher or lower than 100% (9). These 
data strongly suggest that there are no clinically important problems with generic immunosuppressive agents, 
especially with those that meet the EMA criteria, but rather that there are problems with the scientific value, 
relevance and interpretation of smaller studies. 
 
,WVKRXOGDOVREHQRWHGWKDWWKH(0$¶VSUHFDXWLRXVQDUURZLQJRIELRHTXLYDOHQFHOLPLts was specifically implemented 
for situations where it is suspected that plasma level-monitoring will - against the SPC advice - not be complied with; 
such as following a switch from an originator to a generic (7). This narrowing can therefore be seen as a ³safety net´ 
for the use of immunosuppressive generics. This suggests that generic immunosuppressive drugs, used in the correct 
manner by practitioners aware of their precautions, especially the requirement for monitoring of plasma levels at the 
time of switching, may indeed be considered to be bioequivalent and expected to produce outcomes that are smilar 
to those produced by originator products. 
 
This expectation is supported by the fact that generic versions of immunosuppressive medicines (i.e. ciclosporin) 
KDYHEHHQRQWKHPDUNHWLQ(XURSHIRUPRUHWKDQ\HDUVDQGDXWKRULWLHV¶SKDUPDFRYLJLOLDQFHV\VWHPVKDYHQRW
identified any serious issues specific for generic immunosuppressants. Lack of any evidence of problems even after 
an estimated hundreds of thousands of prescribed and dispensed doses, should alleviate major concerns among 
clinicians and patients when considering or undertaking a switch. However, it is expected that further well-designed 
studies with a suitable number of patients will help to fully address any remaining concerns with generic 
  
immunosuppressives. Further education among physicians about the need to reliably monitor blood levels in patients 
when first prescribed generic immunosuppressives will also be needed. Such activities may also help to enhance 
adherence to immunosuppressive medicines, which is a crucial concern in transplant patients (13).   
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Figure 1: Tightened confidence intervals with a NTI, e.g. ciclosporin, required according to EMA rules for AUC and 
Cmax  
 
